JP7286179B2 - Ａｘｌデコイ受容体を用いる転移性癌の治療方法 - Google Patents

Ａｘｌデコイ受容体を用いる転移性癌の治療方法 Download PDF

Info

Publication number
JP7286179B2
JP7286179B2 JP2020523776A JP2020523776A JP7286179B2 JP 7286179 B2 JP7286179 B2 JP 7286179B2 JP 2020523776 A JP2020523776 A JP 2020523776A JP 2020523776 A JP2020523776 A JP 2020523776A JP 7286179 B2 JP7286179 B2 JP 7286179B2
Authority
JP
Japan
Prior art keywords
axl
cancer
aspects
dose
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502334A (ja
JP2021502334A5 (https=
Inventor
マッキンタイア，ゲイル
プロハスカ，デイヴィッド
タビビアザール，レイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravive Biologics Inc
Original Assignee
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aravive Biologics Inc filed Critical Aravive Biologics Inc
Publication of JP2021502334A publication Critical patent/JP2021502334A/ja
Publication of JP2021502334A5 publication Critical patent/JP2021502334A5/ja
Application granted granted Critical
Publication of JP7286179B2 publication Critical patent/JP7286179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
JP2020523776A 2017-11-04 2018-11-05 Ａｘｌデコイ受容体を用いる転移性癌の治療方法 Active JP7286179B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762581671P 2017-11-04 2017-11-04
US62/581,671 2017-11-04
US201862618916P 2018-01-18 2018-01-18
US62/618,916 2018-01-18
US201862681944P 2018-06-07 2018-06-07
US62/681,944 2018-06-07
PCT/US2018/059218 WO2019090227A1 (en) 2017-11-04 2018-11-05 Methods of treating metastatic cancers using axl decoy receptors

Publications (3)

Publication Number Publication Date
JP2021502334A JP2021502334A (ja) 2021-01-28
JP2021502334A5 JP2021502334A5 (https=) 2021-12-16
JP7286179B2 true JP7286179B2 (ja) 2023-06-05

Family

ID=66333375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523776A Active JP7286179B2 (ja) 2017-11-04 2018-11-05 Ａｘｌデコイ受容体を用いる転移性癌の治療方法

Country Status (9)

Country Link
US (2) US20200289613A1 (https=)
EP (1) EP3703731A4 (https=)
JP (1) JP7286179B2 (https=)
KR (1) KR20200085307A (https=)
CN (1) CN111565742B (https=)
AU (2) AU2018359863A1 (https=)
CA (1) CA3080732A1 (https=)
MX (1) MX2020007130A (https=)
WO (1) WO2019090227A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4062914A4 (en) 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
WO2021141892A1 (en) * 2020-01-06 2021-07-15 Aravive Inc. Methods of treating clear cell renal carcinoma (ccrcc) using axl decoy receptors
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy
MX2023000810A (es) * 2020-07-19 2023-05-19 Aravive Inc Metodos de diagnostico para el cancer utilizando receptores señuelo axl.
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
EP4398937A4 (en) * 2021-09-11 2025-07-09 Aravive Inc METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY
CN120418281A (zh) * 2022-12-29 2025-08-01 财团法人生物技术开发中心 靶向PD-L1和中和Gas6之融合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518055A (ja) 2010-01-22 2013-05-20 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 抗転移療法におけるａｘｌシグナル伝達の阻害

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
PL2387395T3 (pl) * 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2894539C (en) * 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10876176B2 (en) * 2014-12-18 2020-12-29 Aravive Biologics, Inc. Antifibrotic activity of GAS6 inhibitor
JP7042739B2 (ja) * 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
US20180140679A1 (en) 2016-11-23 2018-05-24 The Board Of Trustees Of The Leland Stanford Junior University Modulation of axl receptor activity in combination with cytoreductive therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518055A (ja) 2010-01-22 2013-05-20 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 抗転移療法におけるａｘｌシグナル伝達の阻害

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Clin Invest.，2017年，Vol. 127, No. 1，pp. 183-198
Nat Chem Biol.，2014年，10(11)，pp.977-983

Also Published As

Publication number Publication date
CN111565742A (zh) 2020-08-21
EP3703731A1 (en) 2020-09-09
RU2020116224A3 (https=) 2022-05-06
WO2019090227A1 (en) 2019-05-09
JP2021502334A (ja) 2021-01-28
KR20200085307A (ko) 2020-07-14
US20200289613A1 (en) 2020-09-17
CA3080732A1 (en) 2019-05-09
EP3703731A4 (en) 2021-07-21
AU2018359863A1 (en) 2020-07-02
RU2020116224A (ru) 2021-12-06
AU2025201654A1 (en) 2025-03-27
MX2020007130A (es) 2021-02-15
US20240009271A1 (en) 2024-01-11
CN111565742B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
JP7286179B2 (ja) Ａｘｌデコイ受容体を用いる転移性癌の治療方法
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
JP2021113220A (ja) Ｐｄ−ｌ１アンタゴニスト併用療法
KR20260017503A (ko) Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
JP2017506227A (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP2020515609A (ja) がんの治療のための抗ｐｄ−ｌ１抗体およびｄｎａ−ｐｋインヒビターの併用
WO2013017540A1 (en) Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd19 maytansinoid immunoconjugate and rituximab
He et al. Discovery of a novel EGFR-targeting antibody–drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies
US20230277631A1 (en) Diagnostic methods for cancer using axl decoy receptors
US20250123284A1 (en) Diagnostic methods for cancer using ephrinb2 expression
RU2785866C2 (ru) Способы лечения метастатических видов рака с использованием рецепторов-ловушек axl
WO2023247660A1 (en) Combination therapies
HK40030449A (en) Methods of treating metastatic cancers using axl decoy receptors
JP2024533362A (ja) Ａｘｌデコイ受容体を一次治療として使用する局所進行又は転移性膵臓腺がんを治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230517

R150 Certificate of patent or registration of utility model

Ref document number: 7286179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150